tetano
Editor, Senior Moderator
Br J Haematol
. 2022 Mar 14.
doi: 10.1111/bjh.18146. Online ahead of print.
Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia
Polyxeni Delaporta[SUP] 1 [/SUP], Evangelos Terpos[SUP] 2 [/SUP], Elena E Solomou[SUP] 1 [/SUP], Sentiljana Gumeni[SUP] 3 [/SUP], Evangelia Nitsa[SUP] 1 [/SUP], Filia Apostolakou[SUP] 4 [/SUP], Dimitra Kyriakopoulou[SUP] 1 [/SUP], Ioannis Ntanasis-Stathopoulos[SUP] 2 [/SUP], Ioannis Papassotiriou[SUP] 4 [/SUP], Ioannis P Trougakos[SUP] 3 [/SUP], Meletios A Dimopoulos[SUP] 2 [/SUP], Antonis Kattamis[SUP] 1 [/SUP]
Affiliations
Abstract
Patients with transfusion-dependent thalassaemia (TDT) are considered an at increased-risk population for severe and/or morbid coronavirus disease 2019 (COVID-19) infection. Timely vaccination is the main preventive method for severe COVID-19. Different adverse events and reactions after vaccination have been reported, with severe ones being extremely rare. Patients with TDT may have altered immunity due to chronic transfusions, iron overload and chelation therapy, and splenic dysfunction. Here, we show that adult patients with TDT following vaccination with the novel messenger RNA vaccines have mild adverse events and can produce protective antibodies comparable to the healthy population.
Keywords: coronavirus disease 2019 (COVID-19); thalassaemia; vaccines.
. 2022 Mar 14.
doi: 10.1111/bjh.18146. Online ahead of print.
Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia
Polyxeni Delaporta[SUP] 1 [/SUP], Evangelos Terpos[SUP] 2 [/SUP], Elena E Solomou[SUP] 1 [/SUP], Sentiljana Gumeni[SUP] 3 [/SUP], Evangelia Nitsa[SUP] 1 [/SUP], Filia Apostolakou[SUP] 4 [/SUP], Dimitra Kyriakopoulou[SUP] 1 [/SUP], Ioannis Ntanasis-Stathopoulos[SUP] 2 [/SUP], Ioannis Papassotiriou[SUP] 4 [/SUP], Ioannis P Trougakos[SUP] 3 [/SUP], Meletios A Dimopoulos[SUP] 2 [/SUP], Antonis Kattamis[SUP] 1 [/SUP]
Affiliations
- PMID: 35286720
- DOI: 10.1111/bjh.18146
Abstract
Patients with transfusion-dependent thalassaemia (TDT) are considered an at increased-risk population for severe and/or morbid coronavirus disease 2019 (COVID-19) infection. Timely vaccination is the main preventive method for severe COVID-19. Different adverse events and reactions after vaccination have been reported, with severe ones being extremely rare. Patients with TDT may have altered immunity due to chronic transfusions, iron overload and chelation therapy, and splenic dysfunction. Here, we show that adult patients with TDT following vaccination with the novel messenger RNA vaccines have mild adverse events and can produce protective antibodies comparable to the healthy population.
Keywords: coronavirus disease 2019 (COVID-19); thalassaemia; vaccines.